РІВЕНЬ СЕРОТОНІНУ У ХВОРИХ НА ГЕНЕРАЛІЗОВАНИЙ АТЕРОСКЛЕРОЗ ТА ЙОГО ДИНАМІКА ПІД ВПЛИВОМ ЦИЛОСТАЗОЛУ

Tatiana Motsak; Victor Lizogub; Elena Kupchynska; Alexey Bugaytsev

doi:10.32345/USMYJ.2(116).2020.44-57

Tatiana Motsak Department of Internal Medicine No4 O.Bogomolets National Medical University, Ukraine, Kyiv;
Victor Lizogub Department of Internal Medicine No4 O.Bogomolets National Medical University, Ukraine, Kyiv;
Elena Kupchynska SI «National Scientific Center «M.D. Strazhesko Institute of Cardiology, Ukraine, Kyiv
Alexey Bugaytsev JSC «Kyiv Vitamin Plant», Ukraine, Kyiv.

DOI: https://doi.org/10.32345/USMYJ.2(116).2020.44-57

Keywords: generalized atherosclerosis, myocardial ischemia, cognitive function, cilostazol, blood flow rate.

Abstract

The aim of this work is to study the effect of cilostazol on regional hemodynamics, sero- tonin levels and functional activity of the brain, heart, lower extremities in patients with generalized atherosclerosis. A 12-week open-label, randomized, placebo-controlled study included 52 males with generalized atherosclerosis and 26 males with chronic coronary syndrome (comparison group). Pa- tients in the generalized atherosclerosis group were randomized into two subgroups: 26 males in ad- dition to basic therapy received cilostazol at a dose of 100 mg twice daily, and 26 patients who received additional placebo. Patients with generalized atherosclerosis had injury of four vascular territories: cerebral, coronary, mesenteric and lower extremities. It was found that in patients with generalized atherosclerosis, the level of serotonin in plasma exceeded this comparison group by 7.8 times, and a number of indicators were lower - in particular, indicators of volumetric blood flow (p<0,001), cognitive function, painless walking distance. Under the influence of treatment with the addition of cilostazol for 12 weeks before baseline therapy, the condition improved: plasma serotonin levels de- creased 2,9 times (p<0,001), significantly (p<0,001) increased volumetric bold flow in all studied vas- cular territories, which contributed to a decrease in the number of both painful and painless episodes of myocardial ischemia (according to daily electrocardiographic monitoring), increased painless and maximum walking distance, and improved cognitive function of the brain. In the generalized ath- erosclerosis group, who was taking placebo, under the influence of treatment, the changes were not significant. Our data indicate a positive effect of cilostazol as an addition to basic therapy in patients with generalized atherosclerosis and the need for further research in this area.

References

Билютин-Асланян, Р. В., Васильев, А. Г., Родичкин, П. В., Трашков, А. П., & Хайцев, Н. В. (2015). Комбинированные ате- росклеротические повреждения сосудов головного мозга и сердца: факторы риска. Педиатр, 6(1).

Лизогуб, В. Г., Купчинськая, Е., & Бугайцев, А. А. (2018). Цилостазол–антиагрегант с большими перспективами. Ліки України, (2), 218.с.10-15

Максименко, Е. Г., & Савченко, В. Н. (2000). Уровень триптофана и серотонина в условиях судорожной готовности головного мозга. Вестник Харьковского национального университета имени ВН Каразина. Серия «Медицина», (1 (494)).

Поспелова, М. Л., Зайцев, Д. Е., Лепёхина, А. С., Ефимцев, А. Ю., Алексеева, Т. М., & Труфанов, Г. Е. (2019). Когнитивные нарушения у пациентов с асимптомными каротидными стенозами более 70%-показание к оперативному лечению? Современные проблемы науки и образования, (5), 116-116.

Aboyans, V., Ricco, J. B., Bartelink, M. L. E., Björck, M., Brodmann, M., Cohnert, T., ... & Espinola-Klein, C. (2018). 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular European heart jour-

nal, 39(9), 763-816.

Amato, M., Montorsi, P., Ravani, A., Oldani, E., Galli, S., Ravagnani, P. M., & Baldassarre, D. (2007). Carotid intima-media

thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and cor- onary intravascular ultrasound findings. European heart journal, 28(17), 2094-2101.

Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019). Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nature Reviews Cardiology, 16(7), 389-406.

Belagaje, S. R. (2017). Stroke rehabilitation. CONTINUUM: Lifelong Learning in Neurology, 23(1), 238-253.

Cerqueira, N. F., Hussni, C. A., & Yoshida, W. B. (2005). Pathophysiology of mesenteric ischemia/reperfusion: a review. Acta Cirurgica Brasileira, 20(4), 336-343.

Chistiakov, D. A., Ashwell, K. W., Orekhov, A. N., & Bobryshev, Y. V. (2015). Innervation of the arterial wall and its modification in atherosclerosis. Autonomic Neuroscience, 193, 7-11.

Chollet, F., Rigal, J., Marque, P., Barbieux-Guillot, M., Raposo, N., Fabry, V., & Loubinoux, I. (2018). Serotonin selective re-

uptake inhibitors (SSRIs) and stroke. Current neurology and neuroscience reports, 18(12), 100.

El-Merahbi, R., Löffler, M., Mayer, A., & Sumara, G. (2015). The roles of peripheral serotonin in metabolic homeostasis. FEBS letters, 589(15), 1728-1734.

Friedland, S. N., Eisenberg, M. J., & Shimony, A. (2012). Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. The American journal of cardiology, 109(10), 1397-1404.

Il’icheva, R. F., & Dolgosh, S. S. (1980). Change in the activity of the histamine and serotonin systems in acute obstruction of the mesenteric vessels. Biulleten’eksperimental’noi biologii i meditsiny, 89(2), 153-155.

Jang, S. H., Kwon, Y. M., & Chang, M. C. (2015). Serotonin syndrome in stroke patients. Journal of Rehabilitation Medicine, 47(3), 282-285.

Lopez, J. A. G., Brown, B. P., Armstrong, M. L., Piegors, D. J., & Heistad, D. D. (1989). Response of the mesenteric circulation to serotonin in normal and atherosclerotic monkeys: implications for the pathogenesis of non-occlusive intestinal ischaemia. Cardiovas- cular research, 23(2), 117-124.

Martin, A. M., Young, R. L., Leong, L., Rogers, G. B., Spencer, N. J., Jessup, C. F., & Keating, D. J. (2017). The diverse metabolic roles of peripheral serotonin. Endocrinology, 158(5), 1049-1063.

Mauler, M., Bode, C., & Duerschmied, D. (2016). Platelet serotonin modulates immune functions. Hämostaseologie, 36(01), 11-16. Moore, H. M., Drucker, N. A., Hosfield, B. D., Shelley, W. C., & Markel, T. A. (2020). Sildenafil as a Rescue Agent Following

Intestinal Ischemia and Reperfusion Injury. Journal of Surgical Research, 246, 512-518.

Mortensen, J. K., Kraglund, K. L., Johnsen, S. P., Mors, O., Andersen, G., & Buttenschøn, H. N. (2018). The serotonin transporter gene polymorphisms and risk of ischemic stroke. Cerebrovascular Diseases, 45(3-4), 187-192.

Oh, C. M., Namkung, J., Go, Y., Shong, K. E., Kim, K., Kim, H., & Shong, M. (2015). Regulation of systemic energy homeosta-

sis by serotonin in adipose tissues. Nature communications, 6(1), 1-12.

Regensteiner, J. G., Ware Jr, J. E., McCarthy, W. J., Zhang, P., Forbes, W. P., Heckman, J., & Hiatt, W. R. (2002). Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. Journal of the American Geriatrics Society, 50(12), 1939-1946.

Reiter, M., Effenberger, I., Sabeti, S., Mlekusch, W., Schlager, O., Dick, P., & Schillinger, M. (2008). Increasing carotid plaque

echolucency is predictive of cardiovascular events in high-risk patients. Radiology, 248(3), 1050-1055.

Teramoto, Y., Urano, T., Nagai, N., Takada, Y., Ikeda, K., & Takada, A. (1998). Plasma levels of 5-HT and 5-HIAA increased after intestinal ischemia/reperfusion in rats. The Japanese journal of physiology, 48(5), 333-339.

Tóth, Š., Jonecová, Z., Varga, J., Staško, P., Kovavalčinová, B., Maretta, M., & Veselá, J. (2012). Mesenteric ischemia–reperfusion injury: specific impact on different cell populations within the jejunal wall in rats. Acta histochemica, 114(3), 276-284.

Uchiyama, S., Shinohara, Y., Katayama, Y., Yamaguchi, T., Handa, S., Matsuoka, K., ... & Kitagawa, Y. (2014). Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. Cerebrovascular diseases, 37(4), 296-303.

Watanabe, H., Akasaka, D., Ogasawara, H., Sato, K., Miyake, M., Saito, K., ... & Chao, G. (2010). Peripheral serotonin enhances lipid metabolism by accelerating bile acid turnover. Endocrinology, 151(10), 4776-4786.

Xu, L., Cheng, D., Huang, Z., Ding, S., Zhang, W., Tan, H., ... & Yang, X. (2017). Histamine promotes the differentiation of mac- rophages from CD11b+ myeloid cells and formation of foam cells through a Stat6-dependent pathway. Atherosclerosis, 263, 42-52.

Yabut, J. M., Crane, J. D., Green, A. E., Keating, D. J., Khan, W. I., & Steinberg, G. R. (2019). Emerging roles for serotonin in regulating metabolism: New implications for an ancient molecule. Endocrine reviews, 40(4), 1092-1107.

THE LEVEL OF SEROTONIN IN PATIENTS WITH GENERALIZED ATHEROSCLEROSIS AND ITS DYNAMICS UNDER THE INFLUENCE OF CILOSTAZOL

Abstract

References